TIL Therapies market, Size and Share by 2035

Comments · 154 Views

Roots Analysis has done a detailed study on TIL-based Therapies, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

Key Market Insights

Over 75 TIL-based therapies are being evaluated across different stages of preclinical / clinical development either as monotherapies or in combination with other drugs for the treatment of various oncological disorders

Both industry and non-industry players have demonstrated keen interest in the development of novel TIL-based therapies; further, melanoma emerged as the most popular target indication

Majority (56%) of industry players based in North America are actively undertaking efforts for the development / commercialization of TIL-based cell therapies; the industry is dominated by the presence of mid-sized players

Over the past decade, close to 95 clinical trials have been registered across different geographies for the evaluation of TIL-based therapies; extensive efforts are underway to improve the successive generations of such therapies

Close to 55 scientists from renowned universities are presently involved in the clinical development of TIL-based therapies; majority of these KOLs are primarily based in the US and China

Close to 200 players claim to have the required capabilities to manufacture different types of cell therapies; such firms also offer a wide range of services across different stages of product development

A growing interest in development of TIL-based therapies is reflected from the increase in RD agreements in the last few years; majority of the such deals were signed between players based in North America

Several investors, having realized the opportunity within this upcoming segment of T-cell immunotherapy, have invested USD 2.7 billion, across 30 instances, since 2013

With a More than 165 patents have been filed / granted by various stakeholders in order to protect the intellectual property generated within this field

With a growing focus on the development pipeline and encouraging clinical results, the TIL therapies market is anticipated to witness an annualized growth rate of 40%, in the next decade

Table of Contents


1.1. Introduction

1.2. Key Market Insights

1.3. Scope of the Report

1.4. Research Methodology

1.5. Key Questions Answered



3.1. Chapter Overview

3.2. Pillars of Cancer Therapy

3.3. Overview of Immunotherapies

3.4. Fundamentals of Cancer Immunotherapy

3.5. Classification of Cancer Immunotherapies

3.5.1. By Mechanism of Action

3.5.2. By Type of Target

3.5.3. By Approach

3.5.4. By Product Class

3.6. T-Cell Immunotherapies

3.6.1. Historical Evolution

3.6.2. Key Considerations for Developing T-Cell Immunotherapies

3.6.3. Strategies Employed for the Redirection of T-Cells

3.6.4. Manufacturing of Engineered T-Cells

3.6.5. T-Cell Transduction and Transfection Methods

3.7. Tumor Infiltrating Lymphocyte (TIL)-based Cell Therapy

3.7.2. Development of TILs Therapy

3.8. Key Benefits and Roadblocks

3.9. Concluding Remarks


4.1. Chapter Overview

4.2. TIL-based Therapies: Overall Market Landscape

4.2.1. Analysis by Type of Developer

4.2.2. Analysis by Phase of Development

4.2.3. Analysis by Therapeutic Area

4.2.4. Analysis by Key Target Indications

4.2.5. Analysis by Source of T-Cells

4.2.6. Analysis by Route of Administration

4.2.7. Analysis by Dosing Frequency

4.2.8. Analysis by Target Patient Segment

4.2.9. Analysis by Type of Therapy

4.2.10. Most Active Industry Players: Analysis by Number of TIL-based Therapies

4.2.11. Most Active Non-Industry Players: Analysis by Number of TIL-based Therapies

4.3. TIL-based Therapies: Overall Developer Landscape

4.3.1. Analysis by Year of Establishment

4.3.2. Analysis by Company Size

4.3.3. Analysis by Location of Headquarters


5.1. Chapter Overview

5.2. Scope and Methodology

5.3. TIL-based Therapies: Clinical Trial Analysis

5.3.1. Analysis by Trial Registration Year

5.3.2. Analysis by Trial Registration Year and Enrolled Patient Population

5.3.3. Analysis by Trial Status

5.3.4. Analysis by Trial Registration Year and Trial Status

5.3.5. Analysis by Trial Phase

5.3.6. Analysis by Trial Phase and Enrolled Patient Population

5.3.7. Analysis by Target Patient Segment

5.3.8. Analysis by Type of Sponsor / Collaborator

5.3.9. Analysis by Study Design

5.3.10. Most Active Industry Players: Analysis by Number of Registered Trials

5.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials

5.3.12. Word Cloud Analysis: Emerging Focus Areas

5.3.13. Analysis of Clinical Trials by Geography

5.3.14. Analysis of Enrolled Patient Population by Geography


6.1. Chapter Overview

6.2. Assumptions and Key Parameters

6.3. Methodology

6.4. TIL-based Therapies: Key Opinion Leaders

6.4.1. Analysis by Type of Organization

6.4.2. Analysis by Affiliated Organization

6.4.3. Analysis by Qualification

6.4.4. Analysis by Geographical Location of KOLs

6.4.5. KOL Activeness versus KOL Strength

6.4.6. Most Prominent KOLs: Analysis by RA score

6.4.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score


7.2. LN-144 / Lifileucel (Iovance Biotherapeutics)

7.3. LN-145 (Iovance Biotherapeutics)

7.4. ITIL-168 (Instil Bio)

7.5. LTX-315 (Lytix Biopharma)


8.1. Chapter Overview

8.2. Partnership Models

8.3. TIL-based Therapies: Partnerships and Collaborations

8.3.1. Analysis by Year of Partnership

8.3.2. Analysis by Type of Partnership

8.3.3. Analysis by Year of Partnership and Type of Partnership

8.3.4. Analysis by Type of Partner

8.3.5. Most Popular Products: Analysis by Number of Partnerships

8.3.6. Most Active Industry Players: Analysis by Number of Partnerships

8.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships

8.3.8. Analysis by Geography


9.1. Chapter Overview

9.2. Type of Funding

9.3. TIL-based Therapies: Funding and Investment Analysis

9.3.1. Analysis by Year of Investment

9.3.2. Analysis by Amount Invested

9.3.3. Analysis by Type of Funding

9.3.4. Analysis by Type of Investor

9.3.5. Most Active Players: Analysis by Number of Instances

9.3.6. Most Active Investors: Analysis by Amount Invested

9.3.7. Analysis of Amount Invested by Geography

9.3.8. Most Active Investors: Analysis by Number of Funding Instances


10.1. Chapter Overview

10.2. Scope and Methodology

10.3. TIL-based Therapies: Patent Analysis

10.3.1. Analysis by Patent Publication Year

10.3.2. Analysis By Patent Application Year

10.3.3. Analysis by Geography

10.3.4. Analysis by Type of Player

10.3.5. Analysis by CPC Symbols

10.3.6. Word Cloud Analysis: Emerging Focus Areas

10.3.7. Leading Players: Analysis by Number of Patents

10.3.8. TIL-based Therapies: Patent Benchmarking

10.3.9. Analysis By Patent Characteristics

10.3.10. TIL-based Therapies: Patent Valuation


11.1. Chapter Overview

11.2. Overview of Cell Therapy Manufacturing

11.3. Cell Therapy Manufacturing Models

11.3.1. Centralized Manufacturing Model

11.3.2. Decentralized Manufacturing Model

11.4. Scalability of Cell Therapy Manufacturing Processes

11.4.1. Scale-Up

11.4.2. Scale-Out

11.5. Types of Cell Therapy Manufacturers

11.6. Key Challenges Related to Manufacturing of Cell Therapies

11.7. Important Factors for Cell Therapy Manufacturing

11.7.1. Characterization

11.7.2. Cost of Goods

11.8. Automation of Cell Therapy Manufacturing Process

11.9. Cell Therapy Manufacturing Supply Chain

11.10. Comparison of Player Having In-House Capabilities and Contract Manufacturers

11.11. Regulatory Landscape

11.12. Future Perspectives


12.1. Chapter Overview

12.2. Factors Contributing to the High Price of Cell / Gene Therapies

12.3. Pricing Models for T-Cell Immunotherapies

12.3.1. Based on Associated Costs

12.3.2. Based on Availability of Competing Products

12.3.3. Based on Patient Segment

12.3.4. Based on Opinions of Industry Experts

12.4. Reimbursement related Considerations for T-Cell Immunotherapies


13.1. Chapter Overview

3.4. Global TIL-Based Therapies Market, 2022-2035

13.4.1. TIL-based Therapies Market: Analysis by Target Indication

13.4.2. TIL-based Therapies Market: Analysis by Key Players

13.4.3. TIL-based Therapies Market: Analysis by Key Geographical Regio